ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1671973
This article is part of the Research TopicDecoding the immunotherapy paradox: integrative approaches for balancing efficacy and immunotherapy-associated adverse eventsView all 6 articles
Analysis of the Twelve Cases of Immune-Related Myocarditis Caused by Cadonilimab
Provisionally accepted
- 1Gansu Provincial Maternity and Child-care Hospital（Gansu Provincial Central Hospital）, lanzhou, China
- 2Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, changsha, China
- 3Gansu Provincial Maternity and Child Care Hospital, Lanzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
[Abstract] Objective: This study aims to analyze the clinical characteristics of immune-related myocarditis caused by cadonilimab, thereby providing a reference for its safe clinical application. Methods: A retrospective analysis was conducted on the medical records of 12 patients diagnosed with immune-related myocarditis caused by cadonilimab at our hospital between January 1st, 2021 and December 31, 2024. Results: The incidence of immune-related myocarditis caused by cadonilimab was 2.45% (95%CI:1.30%-4.20%). Among the 12 patients who developed immune-related myocarditis, the majority were female (66.7%) and aged 65 years or younger (83.33%). The median time to onset was 49 days(IQR 27.75,78), with 10 cases occurring within 90 days following the initial administration. 7 patients were off-label use. Additionally, 7 patients were accompanied by other immune checkpoint inhibitor (ICI)-related adverse events (irAEs) , such as hypothyroidism, hepatitis and infusion reactions. 9 patients received glucocorticoid treatment and all of the 12 patients showed improvement and recovery. Conclusion: The clinical use of cadonilimab is complex, necessitating individualized monitoring for immune-related myocarditis based on the patient's condition. Furthermore, patient education is essential to ensure medication safety.
Keywords: Cadonilimab, Immune-related myocarditis, cytotoxic T-lymphocyte-associated protein-4, Immunotherapy, Programmed cell death receptor-1 (PD-1)
Received: 23 Jul 2025; Accepted: 30 Sep 2025.
Copyright: © 2025 ZHAO, Chen, Zheng and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jinlan Li, lijinlan@hnca.org.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.